Kow Rebecca L, Strovas Timothy J, McMillan Pamela J, Jacobi Ashley M, Behlke Mark A, Saxton Aleen D, Latimer Caitlin S, Keene C Dirk, Kraemer Brian C
Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health, Care System, Seattle, WA 98108, USA; Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA 98104, USA.
Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health, Care System, Seattle, WA 98108, USA.
Neurobiol Dis. 2021 Jan;147:105148. doi: 10.1016/j.nbd.2020.105148. Epub 2020 Oct 25.
Aging drives pathological accumulation of proteins such as tau, causing neurodegenerative dementia disorders like Alzheimer's disease. Previously we showed loss of function mutations in the gene encoding the poly(A) RNA binding protein SUT-2/MSUT2 suppress tau-mediated neurotoxicity in C. elegans neurons, cultured human cells, and mouse brain, while loss of PABPN1 had the opposite effect (Wheeler et al., 2019). Here we found that blocking poly(A) tail extension with cordycepin exacerbates tauopathy in cultured human cells, which is rescued by MSUT2 knockdown. To further investigate the molecular mechanisms of poly(A) RNA-mediated tauopathy suppression, we examined whether genes encoding poly(A) nucleases also modulated tauopathy in a C. elegans tauopathy model. We found that loss of function mutations in C. elegans ccr-4 and panl-2 genes enhanced tauopathy phenotypes in tau transgenic C. elegans while loss of parn-2 partially suppressed tauopathy. In addition, loss of parn-1 blocked tauopathy suppression by loss of parn-2. Epistasis analysis showed that sut-2 loss of function suppressed the tauopathy enhancement caused by loss of ccr-4 and SUT-2 overexpression exacerbated tauopathy even in the presence of parn-2 loss of function in tau transgenic C. elegans. Thus sut-2 modulation of tauopathy is epistatic to ccr-4 and parn-2. We found that human deadenylases do not colocalize with human MSUT2 in nuclear speckles; however, expression levels of TOE1, the homolog of parn-2, correlated with that of MSUT2 in post-mortem Alzheimer's disease patient brains. Alzheimer's disease patients with low TOE1 levels exhibited significantly increased pathological tau deposition and loss of NeuN staining. Taken together, this work suggests suppressing tauopathy cannot be accomplished by simply extending poly(A) tails, but rather a more complex relationship exists between tau, sut-2/MSUT2 function, and control of poly(A) RNA metabolism, and that parn-2/TOE1 may be altered in tauopathy in a similar way.
衰老会促使诸如tau蛋白等蛋白质发生病理性积累,从而引发像阿尔茨海默病这样的神经退行性痴呆症。此前我们发现,编码聚腺苷酸(poly(A))RNA结合蛋白SUT-2/MSUT2的基因发生功能丧失突变,可抑制秀丽隐杆线虫神经元、培养的人类细胞和小鼠大脑中tau介导的神经毒性,而PABPN1功能丧失则产生相反的效果(惠勒等人,2019年)。在此我们发现,用虫草素阻断聚腺苷酸尾延伸会加剧培养的人类细胞中的tau病变,而敲低MSUT2可挽救这种情况。为了进一步研究聚腺苷酸RNA介导的tau病变抑制的分子机制,我们在秀丽隐杆线虫tau病变模型中检测了编码聚腺苷酸核酸酶的基因是否也能调节tau病变。我们发现,秀丽隐杆线虫ccr-4和panl-2基因的功能丧失突变增强了tau转基因秀丽隐杆线虫的tau病变表型,而parn-2功能丧失则部分抑制了tau病变。此外,parn-1功能丧失会阻止parn-2功能丧失对tau病变的抑制作用。上位性分析表明,sut-2功能丧失可抑制ccr-4功能丧失导致的tau病变增强,并且即使在tau转基因秀丽隐杆线虫存在parn-2功能丧失的情况下,SUT-2过表达也会加剧tau病变。因此,sut-2对tau病变的调节作用相对于ccr-4和parn-2是上位性的。我们发现人类去腺苷酸化酶不会与人类MSUT2在核斑点中共定位;然而,parn-2的同源物TOE1的表达水平与阿尔茨海默病患者死后大脑中的MSUT2表达水平相关。TOE1水平低的阿尔茨海默病患者表现出病理性tau沉积显著增加以及NeuN染色缺失。综上所述,这项研究表明,抑制tau病变不能简单地通过延长聚腺苷酸尾来实现,而是tau、sut-2/MSUT2功能以及聚腺苷酸RNA代谢控制之间存在更复杂的关系,并且parn-2/TOE1在tau病变中可能以类似的方式发生改变。